Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1997 1
1998 3
1999 5
2000 3
2001 1
2002 5
2003 2
2004 3
2005 8
2006 10
2007 9
2008 12
2009 12
2010 23
2011 9
2012 10
2013 15
2014 12
2015 5
2016 13
2017 8
2018 6
2019 3
2020 2
2021 8
2022 8
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis.
Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C. Chen X, et al. Clin Respir J. 2018 Jun;12(6):2065-2074. doi: 10.1111/crj.12774. Epub 2018 Feb 22. Clin Respir J. 2018. PMID: 29393580 Review.
For both PAH and CTEPH, there was no significant difference in mortality or adverse event between bosentan and placebo group. However, bosentan raised the risk of abnormal liver function in both PAH and CTEPH patients. ...Incidence of liver function abnormality is h …
For both PAH and CTEPH, there was no significant difference in mortality or adverse event between bosentan and placebo group. However …
Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
Becattini C, Manina G, Busti C, Gennarini S, Agnelli G. Becattini C, et al. Thromb Res. 2010 Jul;126(1):e51-6. doi: 10.1016/j.thromres.2010.01.007. Epub 2010 Feb 21. Thromb Res. 2010. PMID: 20172593 Review.
We performed a systematic review and meta-analysis aimed at assessing the effects of bosentan therapy in patients with CTEPH. METHODS: We searched in MEDLINE and Embase using the terms 'pulmonary hypertension' AND 'bosentan'. ...Three patient died within 3-6 months …
We performed a systematic review and meta-analysis aimed at assessing the effects of bosentan therapy in patients with CTEPH. METHODS …
Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q, Guo N, Chen J, Parks D, Tian Z. Zhao Q, et al. J Clin Pharm Ther. 2022 Feb;47(2):146-156. doi: 10.1111/jcpt.13481. Epub 2021 Jul 28. J Clin Pharm Ther. 2022. PMID: 34319626 Review.
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no significant difference in 6MWD (MD: -1.32; 95% CI: -27.87, 25.31, SUCRA score: ambrisentan 0.73, bosentan 0.77), BDI (MD: -0.16; 95% …
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no …
The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis.
Kuang HY, Wu YH, Yi QJ, Tian J, Wu C, Shou WN, Lu TW. Kuang HY, et al. Medicine (Baltimore). 2018 Mar;97(10):e0075. doi: 10.1097/MD.0000000000010075. Medicine (Baltimore). 2018. PMID: 29517668 Free PMC article. Review.
BACKGROUND: Oral bosentan has been widely applied in pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). ...Among all studies, 456 patients were diagnosed with PAH-CHD, and 91.7% were treated with oral bosentan. With a term less than …
BACKGROUND: Oral bosentan has been widely applied in pulmonary arterial hypertension associated with congenital heart disease (PAH-CH …
Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension.
Lee YH, Song GG. Lee YH, et al. Korean J Intern Med. 2013 Nov;28(6):701-7. doi: 10.3904/kjim.2013.28.6.701. Epub 2013 Oct 29. Korean J Intern Med. 2013. PMID: 24307846 Free PMC article. Review.
The bosentan therapy group worsened less clinically than the placebo group (OR, 0.252; 95% CI, 0.140 to 0.454; p = 4.6 10(-7)). ...CONCLUSIONS: This meta-analysis shows that bosentan can treat PAH effectively. However, bosentan increased the incidence of abno …
The bosentan therapy group worsened less clinically than the placebo group (OR, 0.252; 95% CI, 0.140 to 0.454; p = 4.6 10(-7)). ...CO …
Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.
METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to …
METHODS AND RESULTS: In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic …
Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Guo L, Liu YJ, Xie ZL. Guo L, et al. Eur Rev Med Pharmacol Sci. 2014;18(5):638-45. Eur Rev Med Pharmacol Sci. 2014. PMID: 24668703 Free article. Review.
CONCLUSIONS: The short-term treatment with oral bosentan could increase walking distance on 6-MWT, and long-term treatment could increase the Resting SpO2 in CHD-PAH patients. Oral bosentan in CHD-PAH patients was safe and well tolerated....
CONCLUSIONS: The short-term treatment with oral bosentan could increase walking distance on 6-MWT, and long-term treatment could incr …
Efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn: a Metaanalysis.
Li LX, Wei B, Yang M, Li M, Jia JJ. Li LX, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2022 Mar 15;24(3):319-325. doi: 10.7499/j.issn.1008-8830.2109151. Zhongguo Dang Dai Er Ke Za Zhi. 2022. PMID: 35351265 Free PMC article. Chinese, English.
The main adverse reactions of bosentan treatment included abnormal liver function, anemia and edema. ...The main adverse reactions of bosentan treatment included abnormal liver function, anemia and edema. ...
The main adverse reactions of bosentan treatment included abnormal liver function, anemia and edema. ...The main adverse reactions of …
A pilot study into bosentan (Tracleer) as an immunomodulating agent in patients with Behcet's disease.
Houwen TBV, Hagen PMV, Kappen JH, Kuijpers RWAM, Daele PLAV, Dik WAV, Laar JAMV. Houwen TBV, et al. Asian Pac J Allergy Immunol. 2022 Dec;40(4):435-441. doi: 10.12932/AP-160919-0648. Asian Pac J Allergy Immunol. 2022. PMID: 32828115 Free article. Clinical Trial.
OBJECTIVE: The aim of our study was to investigate the possible beneficial effect of the ET-1 inhibitor bosentan. METHODS: We performed a prospective double-blind placebo controlled pilot study into the effect and safety of bosentan in BD patients. ...In the bose
OBJECTIVE: The aim of our study was to investigate the possible beneficial effect of the ET-1 inhibitor bosentan. METHODS: We perform …
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. McLaughlin V, et al. Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25. Eur Respir J. 2015. PMID: 26113687 Free article. Clinical Trial.
The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (20 mg three times daily) for 3 months we …
The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this p …
173 results